16 May 2016 - A new approach PHARMAC has used for funding medicines for rare disorders is gaining real traction, says chief executive Steffan Crausaz.

PHARMAC has now approved funding for four medicines from a request for proposals, specifically aimed at medicines for rare disorders.

Steffan Crausaz says the approach succeeded in attracting bids for medicines not previously seen in New Zealand, some of which were now available and funded for people with rare disorders.

“The PHARMAC model has always been flexible enough to consider funding medicines for rare disorders, as well as those for more common conditions,” says Steffan Crausaz.

“This new approach has enabled us to find new funding solutions for rare disorders medicines. We’ve used our evidence-based approach to make decisions on the best value medicines from bids received, and at the same time maintained our ability to fund other medicines as well.

“This really is the PHARMAC model in action – it has enabled us to improve health outcomes for people with rare disorders, and for other New Zealanders, from within the funding available.”

For more details, go to: http://www.pharmac.govt.nz/news/media-2016-05-17-rare-disorders/